Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies
In addition to being the most common primary brain tumor, gliomas are also among the most difficult to diagnose and treat. At present, the “gold standard” in glioma treatment entails the surgical resection of the largest possible portion of the tumor, followed by temozolomide therapy and radiation....
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/20/5041 |
| _version_ | 1797474521865781248 |
|---|---|
| author | Magdalena Gaca-Tabaszewska Joanna Bogusiewicz Barbara Bojko |
| author_facet | Magdalena Gaca-Tabaszewska Joanna Bogusiewicz Barbara Bojko |
| author_sort | Magdalena Gaca-Tabaszewska |
| collection | DOAJ |
| description | In addition to being the most common primary brain tumor, gliomas are also among the most difficult to diagnose and treat. At present, the “gold standard” in glioma treatment entails the surgical resection of the largest possible portion of the tumor, followed by temozolomide therapy and radiation. However, this approach does not always yield the desired results. Additionally, the ability to cross the blood-brain barrier remains a major challenge for new potential drugs. Thus, researchers continue to search for targeted therapies that can be individualized based on the specific characteristics of each case. Metabolic and lipidomic research may represent two of the best ways to achieve this goal, as they enable detailed insights into the changes in the profile of small molecules in a biological system/specimen. This article reviews the new approaches to glioma therapy based on the analysis of alterations to biochemical pathways, and it provides an overview of the clinical results that may support personalized therapies in the future. |
| first_indexed | 2024-03-09T20:32:18Z |
| format | Article |
| id | doaj.art-a30c81288bc44ea4bed5b4fcfaf1d2a2 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:32:18Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a30c81288bc44ea4bed5b4fcfaf1d2a22023-11-23T23:20:57ZengMDPI AGCancers2072-66942022-10-011420504110.3390/cancers14205041Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized TherapiesMagdalena Gaca-Tabaszewska0Joanna Bogusiewicz1Barbara Bojko2Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089 Bydgoszcz, PolandDepartment of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089 Bydgoszcz, PolandDepartment of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-089 Bydgoszcz, PolandIn addition to being the most common primary brain tumor, gliomas are also among the most difficult to diagnose and treat. At present, the “gold standard” in glioma treatment entails the surgical resection of the largest possible portion of the tumor, followed by temozolomide therapy and radiation. However, this approach does not always yield the desired results. Additionally, the ability to cross the blood-brain barrier remains a major challenge for new potential drugs. Thus, researchers continue to search for targeted therapies that can be individualized based on the specific characteristics of each case. Metabolic and lipidomic research may represent two of the best ways to achieve this goal, as they enable detailed insights into the changes in the profile of small molecules in a biological system/specimen. This article reviews the new approaches to glioma therapy based on the analysis of alterations to biochemical pathways, and it provides an overview of the clinical results that may support personalized therapies in the future.https://www.mdpi.com/2072-6694/14/20/5041gliomasmetabolomicslipidomicspharmacotherapypersonalized medicine |
| spellingShingle | Magdalena Gaca-Tabaszewska Joanna Bogusiewicz Barbara Bojko Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies Cancers gliomas metabolomics lipidomics pharmacotherapy personalized medicine |
| title | Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies |
| title_full | Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies |
| title_fullStr | Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies |
| title_full_unstemmed | Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies |
| title_short | Metabolomic and Lipidomic Profiling of Gliomas—A New Direction in Personalized Therapies |
| title_sort | metabolomic and lipidomic profiling of gliomas a new direction in personalized therapies |
| topic | gliomas metabolomics lipidomics pharmacotherapy personalized medicine |
| url | https://www.mdpi.com/2072-6694/14/20/5041 |
| work_keys_str_mv | AT magdalenagacatabaszewska metabolomicandlipidomicprofilingofgliomasanewdirectioninpersonalizedtherapies AT joannabogusiewicz metabolomicandlipidomicprofilingofgliomasanewdirectioninpersonalizedtherapies AT barbarabojko metabolomicandlipidomicprofilingofgliomasanewdirectioninpersonalizedtherapies |